A Considerable Setback For Cancer Trials Because Of COVID-19, IQVIA/CRI Survey Finds

Patient enrollment in clinical trials for cancer drugs was "severely" affected by the COVID-19 pandemic, according to a report published in Nature Reviews Drug Discovery.

Mobile Electronic Traffic Sign stating “expect Delays” taken at sunset with traffic blurred driving past the sign and traffic cones — Clinical trial enrollment issues are affecting cancer drug development • Source: Shutterstock

Clinical trials for cancer drugs were disrupted by the COVID-19 pandemic beginning in late March, according to a survey conducted by the market research firm IQVIA and the Cancer Research Institute (CRI) and published in Nature Reviews Drug Discovery on 18 May.

"Although the data are limited by the sample size, they indicate that patient enrollment in active clinical trials for cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.